Expanded Access to Burosumab

NCT03775187 | Unknown

• 1 other identifier: UX023-EAP
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Individual patient expanded access requests may be considered for patients who have no other treatment options

Conditions

X-linked Hypophosphatemia; Tumor-Induced Osteomalacia

Keywords

Expanded Access; Compassionate Use; XLH; TIO

Interventions

Burosumab BIOLOGICAL

Also known as: UX023, Crysvita®, KRN23

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

Sponsors & Collaborators

• Kyowa Kirin Co., Ltd.: lead

MeSH Terms

Conditions

Familial Hypophosphatemic Rickets; Oncogenic osteomalacia

Interventions

burosumab

Condition Hierarchy (Ancestors)

Rickets, Hypophosphatemic; Rickets; Bone Diseases, Metabolic; Bone Diseases; Musculoskeletal Diseases; Hypophosphatemia, Familial; Renal Tubular Transport, Inborn Errors; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Metal Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Metabolic Diseases; Nutritional and Metabolic Diseases; Calcium Metabolism Disorders; Hypophosphatemia; Phosphorus Metabolism Disorders; Vitamin D Deficiency; Avitaminosis; Deficiency Diseases; Malnutrition; Nutrition Disorders

Central Study Contacts

Development Division Project Management Department

CONTACT

609-919-1100; kkd.clintrial.82@kyowakirin.com

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 11, 2018
• First Posted: December 13, 2018
• Last Updated: March 5, 2025

Record last verified: 2024-09